- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Atwater Malick LLC Trims Holdings in Johnson & Johnson $JNJ
Institutional investor reduces stake in pharmaceutical giant
Apr. 18, 2026 at 7:24am
Got story updates? Submit your updates here. ›
The behind-the-scenes machinery powering a pharmaceutical giant like Johnson & Johnson reflects the industry's financial complexity and operational scale.New Brunswick TodayAtwater Malick LLC, a financial management firm, lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 14.9% during the fourth quarter, according to a recent disclosure with the Securities & Exchange Commission. The firm now owns 31,611 shares of the company's stock, valued at $6.5 million.
Why it matters
Johnson & Johnson is a major pharmaceutical and consumer healthcare company, and changes in institutional ownership of its stock can signal broader trends in the industry and investor sentiment.
The details
Atwater Malick LLC sold 5,542 shares of Johnson & Johnson stock during the fourth quarter, reducing its total position to 31,611 shares. The firm cited portfolio rebalancing and risk management as reasons for the trimmed holding. Johnson & Johnson accounts for 1.8% of Atwater Malick's total assets under management.
- Atwater Malick LLC disclosed the reduced holdings in a filing with the SEC on April 18, 2026.
- The trades occurred during the fourth quarter of 2025.
The players
Atwater Malick LLC
A financial management firm that owns a portfolio of stocks, including a position in pharmaceutical giant Johnson & Johnson.
Johnson & Johnson
A multinational healthcare company that develops, manufactures, and markets pharmaceutical, medical device, and consumer health products.
The takeaway
This transaction highlights the ongoing shifts in institutional ownership of Johnson & Johnson stock, as investors balance the company's market dominance with broader economic and industry trends. The reduced position by Atwater Malick LLC may signal a broader reassessment of risk and portfolio allocations within the healthcare sector.
